

AD/PD 2025 Presentations Relating to Eisai's Key Compounds and Research

Oral Presentations

Asset, Session, Time (Central Europe Time: CET)	Presentation Title
Lecanemab Abeta Targeting Therapies in AD Thursday, April 3, 15:05 – 15:20	Real-World Evidence of Lecanemab Use in the United States
Lecanemab Abeta and Tau Immunotherapies Saturday, April 5, 11:10 – 11:25	Lecanemab-Associated Amyloid-Beta Protofibril in CSF is a Proximal Biomarker of Neurodegeneration Unlike Other Plaque-Associated Biomarkers.
Lecanemab Advances in AD Drug Development Saturday, April 5, 16:40 – 16:55	Lecanemab for Treatment of Individuals with Early Alzheimer's Disease (AD): Results in Apolipoprotein E ε4 (ApoE ε4) Non-carriers or Heterozygotes
E2814 & Lecanemab Tauopathies: Challenges in Targeting Tau Saturday, April 5, 12:40 – 12:55	Clinical Trial Design for Concurrent Anti-Amyloid and Anti-Tau Antibody Therapy for Sporadic Alzheimer's Disease
Biomarkers and Imaging Fluid Biomarkers and Multimodal Imaging for Diagnosis, Prognosis and Disease Progression Thursday, April 3, 15:35 – 15:50	Plasma pTau217 Ratio Predicts the Future Progression of Brain Tau Accumulation in Early Alzheimer's Disease
Biomarkers and Imaging On-demand oral (virtual only) + onsite poster	Simultaneous Prediction of Continuous Brain Amyloid and Tau Levels Using Plasma pTau217 Ratio in Preclinical and Early Alzheimer's Disease

Poster Presentations

Asset / Project	Presentation Title
Lecanemab	Lecanemab Long-Term Efficacy and Safety in the Asia Region: A Subgroup Analysis from the Phase 3 Clarity AD Trial
Tau / Tauopathies	An Intraneuronal Tau Aggregation Model of Human iPSC-Derived Neurons Without Tau Seed Addition
Biomarkers and Imaging	Reviewing Scientific and Regulatory Aspects of Tau PET Implementation as a Surrogate Endpoint in Alzheimer's Disease Clinical Studies
Biomarkers	A Prospective, Observational Study Investigating the Real-World Implementation of Confirmatory Diagnostic Blood-Based Biomarkers for Early Alzheimer's Disease: A Feasibility Assessment

Biomarkers	Health Care Providers' Perspectives on the Real-World Use of Confirmatory Diagnostic Blood-Based Biomarkers for Early Alzheimer's Disease
General AD	Natural History of All-Cause Mortality in Patients with Mild Cognitive Impairment and Alzheimer's Dementia Among United States Medicare Beneficiaries
General AD	Estimating the Treatable Population for Anti-Amyloid Therapy in France
General AD	Comparison of Contemporary Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) Disease Progression Models in Alzheimer's Disease
Biomarkers (Sysmex)	Development of a Highly Specific P-Tau205 Assay Using a Fully Automated Immunoassay System
Biomarkers (Shimadzu)	Performance of Plasma A β Biomarkers in Predicting Amyloid Positivity and Clinical Progression

Eisai-Sponsored Symposium: Industry Symposium 09

Thursday, April 3, 18:40 – 20:15 (CET)

Symposium Title: Bridging the Gap in Alzheimer's Disease: From Pathophysiology to Treatment Strategy
